You are accessing a medical content website
Are you a health professional?

Revista Española de Cardiología (English Edition) Revista Española de Cardiología (English Edition)
Rev Esp Cardiol. 2017;70:713-9 - Vol. 70 Num.09 DOI: 10.1016/j.rec.2016.11.024

Thirty-day Outcome Following CoreValve Evolut R Transcatheter Aortic Valve Implantation: An All-comers Prospective Study

Nils Perrin a,, Marco Roffi a, Angela Frei a, Anne-Lise Hachulla b, Christoph Ellenberger c, Hajo Müller a, Mustafa Cikirikcioglu d, Marc Licker c, Stephane Noble a

a Division of Cardiology, University Hospital of Geneva, Geneva, Switzerland
b Department of Radiology, University Hospital of Geneva, Geneva, Switzerland
c Department of Anesthesiology, University Hospital of Geneva, Geneva, Switzerland
d Division of Cardiovascular Surgery, University Hospital of Geneva, Geneva, Switzerland

Refers to


Transcatheter aortic valve implantation. Aortic valve stenosis. Self-expanding valve. Paravalvular leak. Pacemaker implantation. Evolut R.


Introduction and objectives

There are scarce clinical outcomes data on the new generation recapturable and repositionable CoreValve Evolut R.


Data on all-comer patients undergoing transcatheter aortic valve implantation (TAVI) with the Evolut R for severe symptomatic aortic stenosis at a single center were prospectively collected between February 2015 and April 2016. Clinical endpoints were independently adjudicated according to the Valve Academic Research Consortium-2 criteria. Primary outcomes consisted of early safety composite endpoints and 30-day device success. The incidence of new permanent pacemaker implantation was recorded.


Among the 83 patients undergoing TAVI during this period, 71 (85.5% of the population; median age, 83.0 [interquartile range, 80.0-87.0] years; Society of Thoracic Surgeons scores, 4.8 ± 3.5%) were suitable for Evolut R implantation and were included in the analysis. Repositioning was performed in 26.8% of the procedures. The early safety composite endpoint was observed in 11.3% of patients at 30 days, with 2.8% all-cause mortality. Device success was documented in 90.1% of patients. Paravalvular leakage was less than grade II in 98.4% of patients. The mean transvalvular aortic gradient was reduced from 42.5 ± 14.5 mmHg at baseline to 7.7 ± 4.0 mmHg at discharge (P < .0001 vs baseline). New permanent pacemaker implantation was required in 23.9% of patients.


The new generation Evolut R is suitable for most patients and shows high device success and acceptable mortality in an unbiased, consecutive, all-comer population at a single center performing TAVI exclusively with Medtronic valves.

1885-5857/© 2017 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved